Clinical utility of positron emission mammography.
Clinical utility of positron emission mammography.
Proc (Bayl Univ Med Cent). 2013 Jul;26(3):314-9
Authors: Glass SB, Shah ZA
Abstract
Several imaging modalities have been introduced over recent years to better screen for and stage breast cancer. Positron emission mammography (PEM) has been approved by the US Food and Drug Administration and introduced into clinical use as a diagnostic adjunct to mammography and breast ultrasonography. PEM has higher resolution and a more localized field of view than positron emission tomography-computed tomography and can be performed on patients to stage a newly diagnosed malignancy. Review of mammograms together with magnetic resonance or PEM images improves detection of disease.
PMID: 23814402 [PubMed]
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Glass SB, Shah ZA Tags: Proc (Bayl Univ Med Cent) Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | CT Scan | Food and Drug Administration (FDA) | Mammography | PET Scan | Universities & Medical Training